CAR-T细胞治疗后基于影像的毒性与反应模式评估
该单中心回顾性研究纳入38例接受CAR-T输注的难治性B细胞淋巴瘤患者,发现≥2级细胞因子释放综合征(CRS)与胸部影像异常(胸腔积液、肺不张)相关,神经影像在≥2级ICANS中阳性率43%,最佳治疗反应完全缓解率达56%。
要点
- ≥2级CRS患者胸部影像异常比例更高(71% vs 21%),需关注胸腔积液和肺不张。
- CAR-T治疗后评估疗效可采用Deauville五分法,完全缓解率较高。
- ≥2级ICANS患者神经影像阳性率有限,影像阴性不能排除神经毒性。
关键影像表现/征象
- ≥2级ICANS患者神经影像阳性率为3/7(43%)。
诊断标准与关键数值
- CRS和ICANS分级采用ASTCT共识标准。
- 疗效评估采用Deauville五分法,完全缓解20/36(56%),部分缓解7/36(19%),疾病稳定1/36(2.8%),疾病进展8/36(22%)。
临床应用与阅片要点
- CAR-T治疗后出现≥2级CRS时,应仔细评估胸部影像有无胸腔积液和肺不张。
- 神经影像阳性率有限,ICANS诊断主要依赖临床,影像用于排除其他病因。
- 疗效随访报告应采用Deauville五分法进行结构化描述。
局限性
- 单中心回顾性研究,样本量较小(38例)。
- 神经影像评估例数少(仅7例≥2级ICANS)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Chimeric antigen receptor (CAR) T-cell immunotherapy is increasingly used for refractory lymphoma but may lead to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Imaging may assist in clinical management. Associations between CRS or ICANS grade and imaging findings remain not fully established. Purpose To determine associations between imaging findings and clinical grade of CRS or ICANS, evaluate response patterns, and assess imaging use following CAR T-cell treatment. Materials and Methods Patients with refractory B-cell lymphoma who received CAR T-cell infusion between 2018 and 2020 at a single center were analyzed retrospectively. Clinical CRS or ICANS toxicity grade was assessed using American Society for Transplantation and Cellular Therapy, or ASTCT, consensus grading. Thoracic and head images (radiographs, CT scans, MRI scans) were evaluated. Associations between imaging findings and clinical CRS or ICANS grade were analyzed. Wilcoxon signed-rank and χ2 tests were used to assess associations between thoracic imaging findings, clinical CRS toxicity grade, and imaging-based response. Response to therapy was evaluated according to Deauville five-point scale criteria. Results A total of 38 patients (mean age ± standard deviation, 59 years ± 10; 23 men) who received CAR T-cell infusion were included. Of these, 24 (63% [95% CI: 48, 79]) and 11 (29% [95% CI: 14, 44]) experienced clinical grade 1 or higher CRS and ICANS, respectively. Patients with grade 2 or higher CRS were more likely to have thoracic images with abnormal findings (10 of 14 patients [71%; 95% CI: 47, 96] vs five of 24 patients [21%; 95% CI: 4, 37]; P = .002) and more likely to have imaging evidence of pleural effusions (five of 14 [36%; 95% CI: 10, 62] vs two of 24 [8.3%; 95% CI: 0, 20]; P = .04) and atelectasis (eight of 14 [57%; 95% CI: 30, 84] vs six of 24 [25%; 95% CI: 7, 43]; P = .048). Positive imaging findings were identified in three of seven patients (43%) with grade 2 or higher ICANS who underwent neuroimaging. The best treatment response included 20 of 36 patients (56% [95% CI: 39, 72]) with complete response, seven of 36 (19% [95% CI: 6, 33]) with partial response, one of 36 (2.8% [95% CI: 0, 8]) with stable disease, and eight of 36 (22% [95% CI: 8, 36]) with progressive disease. Conclusion Thoracic imaging findings, including pleural effusions and atelectasis, correlated with cytokine release syndrome grade following chimeric antigen receptor (CAR) T-cell infusion. CAR T-cell therapy yielded high response rates. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Langer in this issue.
引用
- Smith, Kikano, Tirumani, et al. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Radiology. 2021. PMID: 34751616. doi:10.1148/radiol.2021210760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。